Cross-sectional and Longitudinal Relationship between Sex Hormones and Six Epigenetic Clocks in Older Adults: Results of the Berlin Aging Study II (BASE-II)

Hannah Schmid¹, Valentin Max Vetter¹, Jan Homann², Vivien Bahr¹, Christina M. Lill^{2,3}, Vera Regitz-Zagrosek^{4,5}, Lars Bertram⁶, Ilja Demuth^{1,7}

¹Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Endocrinology and Metabolic Diseases (including Division of Lipid Metabolism), Biology of Aging working group, Augustenburger Platz 1, 13353 Berlin, Germany

²Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany

³Ageing Epidemiology Research Unit (AGE), School of Public Health, Imperial College London, London, UK

⁴Institute for Gender in Medicine, Center for Cardiovascular Research, Charité -Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt -Universität zu Berlin and Berlin Institute of Health, Berlin, Germany

⁵Department of Cardiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland

⁶Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), University of Lübeck, Lübeck, Germany

⁷Charité - Universitätsmedizin Berlin, BCRT - Berlin Institute of Health Center for Regenerative Therapies, Berlin, Germany

Corresponding author:

Ilia Demuth (Ph.D.) Charité - Universitätsmedizin Berlin Lipid Clinic at the Interdisciplinary Metabolism Center, Biology of Aging Group Augustenburger Platz 1 13353 Berlin

Email: ilja.demuth@charite.de Phone: ++49 30 450 569 143 FAX: ++49 30 450 566 904

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Background Beyond their essential roles in regulating reproduction and development, sex

hormones play a crucial role in the aging processes. Observational studies have indicated that

low sex hormone concentrations in older age are associated with adverse health events. DNA

methylation age acceleration (DNAmAA) estimated from epigenetic clocks quantifies

differences in biological aging. DNAmAA was previously shown to be associated with age at

menopause, ovariectomy, hormone replacement therapy and testosterone level.

Methods We analysed the relationship between estradiol, dehydroepiandrosterone sulfate

(DHEAS) and the Free Androgen Index (FAI) with DNAmAA estimators from six epigenetic

clocks (Horvath's, Hannum's, 7-CpG clock, PhenoAge, GrimAge, DunedinPACE) in 1,404

participants of the Berlin Aging Study II (BASE-II, mean age at baseline 68.7 ±3.7 years, 48%

women). The relationship was investigated in multiple linear regression models cross-

sectionally at two time points and longitudinally over on average 7.3 years of follow-up.

Results We did not observe any consistent associations between the sex hormones and

DNAmAA estimators investigated. However, we found several nominal associations

(alpha=0.05) of unclear relevance. For instance, we identified an inverse association between

DHEAS and Horvath's DNAmAA, i.e. a reduced biological age with higher DHEAS levels in

men at baseline. In women we found an inverse association between estradiol and

DunedinPACE (baseline) and a positive association with GrimAge (follow-up). In longitudinal

analyses, ΔDHEAS and ΔDunedinPACE were inversely associated in both sexes.

Conclusions Our results suggest that sex hormones play at best a minor role with respect to

2

biological aging in the older population studied here.

Introduction

Biological aging refers to differences in the aging process in people of the same chronological

age. One of the latest and most promising biomarker of aging is the DNA methylation age

(DNAmA) and its deviation from chronological age, DNAmA acceleration (DNAmAA) 1,2,

which are calculated from DNA methylation data by epigenetic clock algorithms.

To date, numerous epigenetic clocks are available that mostly differ in the way they were

developed and the number and location of cytosine-phosphate-guanine (CpG) sites they include

³⁻⁸. Previous analyses showed differences in the clock's ability to predict morbidity and age-

related pathologies independent of chronological age 1,9,10. First generation clocks such as

Horvath's, Hannum's and the 7-CpG clock are designed to predict chronological age ³⁻⁵. Second

generation clocks like GrimAge and PhenoAge are highly correlated with age associated

pathologies and lifespan ^{6,7}. DunedinPACE, a third generation clock, is designed to capture an

individual's pace of aging as well as differences from a normal aging rate 8.

Sex hormones have been recognised as factors involved in the aging processes, in addition to

their essential function in regulating reproduction and development ^{11,12}. In general, estrogens

such as estradiol are distinguished from gestagens and androgens including testosterone and

dehydroepiandrosterone sulfate (DHEAS). Over the life course, humans experience profound

changes in sex hormone concentrations ¹². In women, estradiol declines rapidly to

approximately 20% of its maximum premenopausal concentration after the menopause ¹³. In

contrast, the testosterone concentration in men peaks around the age of thirty followed by a

gradual decrease of one to two percent per year ¹⁴. In both sexes, the DHEAS level decreases

slowly starting in the third decade and resulting in a reduction by approximately 80% of its

maximum around the seventh decade ¹⁵. The close temporal association between the decline in

sex hormones and the age-related loss of physical abilities suggests a causal interaction ¹². This

3

assumption is further supported by findings from observational studies that indicate an

association of low sex hormone concentrations in older age with adverse health events ¹⁶⁻¹⁸.

Some studies suggest that the decline in DHEAS is associated with a higher mortality risk in

men ^{19,20}. DHEAS was referred to as an "anti-aging hormone" ²¹ and is available as an over-

the-counter supplement in some countries although there is no consensus on its effectiveness

²². Low levels of testosterone were suggested as a risk factor for short- and long-term mortality

in older men ²³⁻²⁵. In older women, a long reproductive period and late onset of menopause are

related to longevity and reduced risk of mortality ²⁶⁻²⁸. Premature loss of ovarian estrogens is

associated with multimorbidity, while estrogen substitution showed protective effects ²⁹.

Because of these properties and associations, the relationship of sex hormones and biological

age is of high interest. Since effects of sex hormones on overall DNAm levels were shown

before, an association of sex hormone concentrations and DNAmAA seems biologically

plausible ^{30,31}. Indeed, studies in mice showed an accelerated epigenetic age after ovariectomy

³² and in postmenopausal women, associations between early age at menopause and higher

GrimAge and Horvath's DNAmAA have been reported ^{7,33}. Furthermore, Levine and

colleagues suggested that biological aging processes accelerate when women enter the post-

reproductive phase and that postmenopausal use of hormone replacement therapy (HRT)

decreases epigenetic age in some tissues ³³. A recent study found an inverse association between

GrimAge and PhenoAge DNAmAA, respectively, and testosterone in men ³⁴. Since stronger

associations were reported for bioavailable testosterone ³⁴, we used the Free Androgen Index

(FAI) as an indicator of the free, SHBG-unbound proportion of testosterone in our study ³⁵.

Despite these initial findings suggesting an association between sex hormones and DNAmAA,

their potential cross-sectional and longitudinal relationship at different time points has not been

studied yet. Thus, the objective of this study was to analyse the relationship between sex

hormones (estradiol, DHEAS and the FAI) with DNAmAA estimators employing six different

epigenetic clocks at two time points about seven years apart and to investigate the change of

these variables over the observation period. Based on the previously reported results discussed above, we hypothesised that sex hormone concentrations are inversely associated with DNAmAA and that the association is also reflected in our longitudinal data.

Methods

Study population

Participants of the Berlin Aging Study II (BASE-II) cohort were recruited from the greater

metropolitan area of Berlin, Germany. The multidisciplinary BASE-II aims to identify

mechanisms and factors contributing to a healthy aging process. A subsample consisting of

1,671 older participants (aged ≥60 years) from the BASE-II were medically assessed at baseline

between 2009 and 2014 ³⁶. As part of the GendAge study, 1083 participants were reassessed

with a mean follow-up time of 7.4 years (SD=1.5) between 2018 and 2020 ³⁷. Cohort

characteristics are shown in Table 1 and Supplementary Table 1.

Sample selection

Composition of participant numbers and final analytical datasets at baseline and follow-up are

represented in Figure 1. The follow-up data set comprises 17 additional participants who were

not medically examined in the baseline assessment. Women who reported taking oral or

transdermal estrogen-containing HRT within one year prior to the baseline assessment were

excluded from the baseline and longitudinal analyses. At follow-up no information on HRT

cessation was available. Following the maximum duration of HRT recommended in the

literature, we did not exclude women from the follow-up analyses ³⁸. DHEAS data of three men

and one woman were excluded from the baseline dataset due to extremely high values (> 7 SD

from the mean).

DNA Methylation Data

Estimation of DNAmA was based on three first-generation (Horvath's ³, Hannum's ⁴, 7-CpG

6

clock ⁵), two second-generation (PhenoAge ⁶, GrimAge ⁷) and one third-generation epigenetic

clock (DunedinPACE 8). DNAm data originated from leukocyte DNA from whole blood

samples drawn at baseline and follow-up assessment. Blood samples for sex hormone

measurement were taken from the same blood draws. Methylation data was obtained using two methods. For Horvath's ³, Hannum's ⁴, PhenoAge ⁶, GrimAge ⁷ methylation age and DunedinPACE ⁸, methylation data was measured with the "Infinium MethylationEPIC" array (Illumina, Inc., USA). Detailed information about the sample handling and data processing were reported before ³⁹. DunedinPACE was calculated as instructed in the original publication ⁸. A more detailed description of the methods can be found in ref. ³⁹. For the 7-CpG clock measurement ⁴⁰, DNAm data was obtained using methylation-sensitive single nucleotide primer extension (MS-SNuPE). For a detailed description of the laboratory protocol see reference ^{5,40}. DNAmAA was calculated as the unstandardized residual resulting from regressing calculated DNAmA on chronological age while adjusting for blood cell counts (neutrophils, monocytes, lymphocytes, eosinophils) ^{9,40}. Blood cell composition was measured by an accredited laboratory (Labor Berlin GmbH, Berlin, Germany) using flow cytometry.

Sex hormones

Blood was drawn from all participants after an >8h fasting period and kept at 4–8 °C until analysis on the same day. Sex hormones were measured in serum samples by an accredited laboratory (Labor Berlin GmbH, Berlin, Germany) using fluoro- (estradiol, total testosterone (TT)), radio- (DHEAS) and chemiluminescentimmunoassays (sex hormone-binding globulin (SHBG)). During the study period, laboratory methods for measurement of sex hormones changed to electrochemiluminescence immunoassays (ECLIA). For further details we refer to the Supplementary Methods. In the final dataset, n=152 (estradiol, TT and SHBG) and n=39 (DHEAS) participants were affected by the change. A comparison of methods conducted by the accredited laboratory showed a high degree of comparability between the methods used $(R^2=0.95 \text{ and } 0.97, \text{ data not shown})$. The FAI was calculated by using the formula: TT (nmol/l) × 100 / SHBG (nmol/l) 35 .

Covariates

Covariates were selected based on commonly employed factors within the field ³⁴. Smoking behaviour was assessed in pack years during a one-on-one interview by trained study personnel. Daily intake of alcohol (g/d) was assessed using the European Prospective Investigation into Cancer and Nutrition Food Frequency Questionnaire (EPIC-FFQ) ⁴¹. Body Mass Index (BMI, kg/m2) was calculated from height and weight measured with an electronic measuring station (seca 763 measuring station, SECA, Germany). Information on menopausal status, medication and use of HRT, including initiation and cessation of HRT, were self-reported and based on

Statistical analysis

medical reports when available.

Statistical analyses were carried out using the IBM SPSS software package (IBM Corp. Released 2023. IBM SPSS Statistics for Windows, Version 29.0.2.0 Armonk, NY: IBM Corp. To account for sex-dependent hormone profiles, all statistical procedures were carried out in sex-stratified subgroups. Distribution of sex hormone data was visually inspected and found to be skewed. Therefore, non-parametric tests were conducted. Spearman correlation coefficients were calculated. The DNAmAA estimators were treated as a dependent variable in the multiple linear regression analyses. Linear regression models were adjusted for chronological age, BMI, pack years and alcohol intake (g/d). For longitudinal analyses, change in DNAmAA and sex hormones (denoted by Δvariable) was calculated as the difference between values at follow-up and baseline examination and found to be normally distributed. Pearson correlation coefficients were calculated. Linear regression analyses of ΔDNAmAA on Δsex hormones were adjusted for baseline variables (chronological age, sex hormone concentration, DNAmAA, pack years, alcohol intake (g/d), BMI and years since baseline assessment). Only participants with no missing values in the variables included in the respective analyses were considered (available case analysis). This resulted in varying numbers of complete cases depending on the clock and

hormone analysed. A p-value below 0.05 was considered as statistically significant. Due to the explorative character of the study we did not correct for multiple testing.

Results

Descriptive Statistics

The baseline sample consisted of 1,404 participants (48% women). As part of the follow-up

examination 1,015 participants (49% women) were reassessed on average 7.3 years (SD=1.5)

later. The mean age at baseline was 68.4 years (SD=3.6) for women and 69.0 years (SD=3.8)

for men. At baseline all women were postmenopausal with a mean interval of 18.7 years since

menopause (SD=7.3, n=668) and 49.7 (SD=6.0) years as the average age at menopause. In men

and women, median DHEAS concentration and the FAI decreased significantly between the

assessments (Wilcoxon signed-rank test, p<0.001, Table 2). An increase in median estradiol

concentration was found among men (p<0.001). A statistically significant increase in GrimAge

DNAmAA by 0.38 years was shown for men (paired t-test p<0.001, Table 2), while GrimAge

DNAmAA decreased significantly by 0.33 years in women (p=0.004). In both sexes, there was

a significant increase in DunedinPACE by 0.07 years (p<0.001).

Cross-sectional analyses: baseline

Baseline analyses indicated weak correlations (Spearman's rho) between sex hormones and

DNAmAA estimators ranging from r=-0.06 to 0.13 for men and from r=-0.07 to 0.10 for women

(Supplementary Table 2). After adjustment for potential confounders an inverse association of

DHEAS with Horvath's DNAmAA (β=-0.0007, p=0.032, Table 3) was found in linear

regression analyses for men. To illustrate, a decrease in Horvath's DNAmAA by 0.45 years for

every increase in DHEAS of one SD was observed. In women, estradiol was inversely

associated with DunedinPACE (β=-0.0004, p=0.032, Table 3). Every one SD increase in

estradiol was associated with a 0.01 year decrease in DunedinPACE. Cross-sectional analyses

on the baseline dataset revealed no further relevant associations (see Supplementary Table 3).

Cross-sectional analyses: follow-up

Similar to baseline analyses, weak correlations were found between follow-up DNAmAA

estimators and sex hormone level ranging from r=-0.11 to 0.10 for men and r=-0.08 to 0.09 for

women (Supplementary Table 2). Adjusted linear regression analyses for women revealed a

weak positive association between estradiol and the GrimAge DNAmAA (β =0.002, p=0.036,

Supplementary Table 4). All other cross-sectional analyses on the follow-up dataset did not

show any recurrent associations between sex hormones and DNAmAA (see Supplementary

Table 4).

Longitudinal analyses

To assess whether changes in sex hormone concentrations were related to changes in DNAmAA

over the follow-up period, we conducted longitudinal analyses. Weak significant correlation

coefficients (Pearson) were found between ΔDHEAS and ΔDunedinPACE for men (r=-0.18,

p<0.001) and women (r=-0.11, p=0.018, Supplementary Table 2 and Supplementary Figure 1).

After covariate adjustment ΔDHEAS showed an inverse association with ΔDunedinPACE in

linear regression analyses for both men (β =-0.00002, p=0.022, Table 4) and women (β =-

0.00003, p=0.005). Each one SD increase in DHEAS concentration over the assessment period

was associated with a decrease in the pace of aging of 0.009 (men) and 0.01 (women) years,

respectively, as measured by DunedinPACE. No further noteworthy associations were found

between ΔDNAmAA and Δsex hormone levels (see Supplementary Table 5). Additionally, we

conducted a subgroup analysis of participants who experienced a longitudinal hormone decline

greater than the median (Supplementary Table 6). Here, no substantial differences from the

11

overall findings were observed.

Discussion

In this study, we investigated the relationship between estradiol, DHEAS and the FAI with biological age estimated from first-, second- and third-generation epigenetic clocks in crosssectional and longitudinal data of BASE-II participants aged ≥60 years. Generally, no consistent and clinically relevant relationship was found between any of the sex hormones and DNAmAA estimators analysed in this study. Despite this overall lack of significant relationships we observed several nominal associations of unclear relevance. For instance, we identified a weak inverse association between DHEAS and Horvath's DNAmAA in men at baseline. For women we found weak inverse associations between estradiol and DunedinPACE (baseline) and positive associations with GrimAge (follow-up). In longitudinal analyses, there was a weak inverse association between $\Delta DHEAS$ and $\Delta DunedinPACE$, which was present in both sexes. To date, only one study has assessed the relationship between epigenetic clocks as measures of biological aging and sex hormones. In that study by Kusters and colleagues, data of three population-based cohorts of similar age compared to the group of older BASE-II participants were examined cross-sectionally 34. They found that higher testosterone was associated with lower GrimAge and PhenoAge DNAmAA in men. For six more age acceleration measures they did not find significant associations ³⁴. Regarding the age-related reduction in testosterone in men, studies found that lower testosterone levels were associated with increased mortality risk in older age ^{23-25,42}. Testosterone replacement in testosterone deficient men, on the other hand, decreased mortality ^{43,44}. Supporting this direction of effect, Kusters and colleagues suggested that the adverse health outcomes associated with lower testosterone might be moderated by accelerated epigenetic aging ³⁴. While, in our fully adjusted models, we could not replicate this

finding, the direction of the (non-significant) relationship of the FAI with GrimAge and

12

DunedinPACE was in line with the results reported by Kusters and colleagues.

In our study, we observed an inverse association between estradiol and DunedinPACE in

women at baseline, whereas at follow-up, estradiol levels were positively associated with the

GrimAge clock. Given the inconsistent associations observed across our analyses and the small

effect sizes, we consider it unlikely that these findings have relevant clinical implications.

Furthermore, the lack of a meaningful relationship between estradiol and the DNAmAA

estimators investigated here suggests that estradiol may not be a major driver of the accelerated

rate of biological aging in women after the menopause ³³. Regarding higher postmenopausal

estradiol levels and the use of HRT, both health benefits and risks have been reported ⁴⁵⁻⁴⁷.

Studies also suggested that survival benefits of postmenopausal HRT may diminish over time

⁴⁸. Thus, while estradiol's influence on aging is complex, our results do not support a strong

role for estradiol in mediating these effects through the DNAmAA mechanisms in the older

women studied here.

The reputation of DHEAS as an anti-aging hormone stems from studies that have found a higher

mortality risk ^{19,49,50} and a reduced physical capacity in association with lower DHEAS levels

^{19,51}. Fahy and colleagues published a study on epigenetic age reversal involving DHEA

supplementation suggesting a potential positive impact of higher DHEAS levels on biological

aging ⁵². Therefore, we assumed an inverse association to be present in our data. Indeed, we

found higher DHEAS levels associated with slower epigenetic aging as measured by Horvath's

clock in cross-sectional analyses in men. With each one SD increase in DHEAS, Horvath's

DNAmAA decreased by 0.45 years. Also, participants of both sexes exhibiting an increase in

DHEAS concentration of one SD over the assessment period of on average 7.3 years, decreased

in their pace of aging (DunedinPACE) by 0.009 and 0.01 years, respectively. Our findings

suggest that increases in DHEAS levels are associated with a slightly slower rate of biological

aging (DunedinPACE and Horvath's DNAmAA) thereby supporting the direction of an effect

reported before. However, the effect size estimate was relatively small, and additional research

would be needed to further investigate clinical relevance and potential underlying mechanisms.

We note that the lack of consistent associations in this study does not necessarily exclude the

presence of a relationship between sex hormone levels and DNAmAA. The lack of noteworthy

findings may also be due to one or several of the limitations of our study. First, we were not

able to investigate bioavailable hormones due to lack of albumin measurement at follow-up.

However, as a proxy and commonly used parameter to estimate the unbound testosterone

fraction we used the FAI in our study ³⁵. Second, around a third of the baseline participants

were not followed up, which possibly introduces a selection bias. However, a comparison of

sex hormone levels between participants with baseline and follow-up data and those lost to

follow-up revealed no statistically significant differences, except that the dropout group had a

higher average age (Supplementary Table 7). Third, despite the fact that with n=1,404 our

sample size was relatively large, we cannot exclude the possibility that the lack of significant

findings may be due to insufficient power, especially to detect small effects. Finally, as

previously reported, the study population investigated here tends to have an above-average

health status, which limits the generalisability of the results to the general population.

Strengths of this study include the availability of six different epigenetic clocks and four sex

hormones at two time points with a mean follow-up time of 7.3 years. This allowed us to

investigate the long-term relationships between sex hormones and DNAmAA, in addition to

cross-sectional analyses, which was not done before. Moreover, due to the detailed information

on hormone intake and medication, it was possible to exclude participants who were taking

exogenous sex hormones. Information on potentially confounding factors such as BMI,

cigarette smoking and alcohol intake were available, which allowed us to control for these

14

factors.

The age-related decline in sex hormones has substantial implications for the health and quality

of life in the older population. Our study provides explorative insights into the cross-sectional

and longitudinal relationship between sex hormones and DNAmAA in older adults. Future

studies with longitudinal measurements of sex hormones and DNAmAA in a study population

that includes participants at the age of hormonal transition are needed to further investigate the

relationship between biological aging and sex hormone levels.

Conclusion

In this study, we cross-sectionally and longitudinally investigated the relationship between

epigenetic clocks and sex hormones in 1,404 participants aged ≥60 years over a 7.3-year follow-

up period. Generally, we did not observe a consistent relationship between estradiol, DHEAS,

the FAI and epigenetic age as assessed by six different DNAmAA estimators. This suggests

that sex hormones play at best a minor role with respect to biological aging in the older

15

population studied here.

Acknowledgments

This work was supported by grants of the Deutsche Forschungsgemeinschaft (project number

460683900 to ID & LB), the ERC (as part of the Lifebrain project to LB), and the Cure

Alzheimer's Fund (as part of the CIRCUITS consortium to LB). Additional funds supporting

this research came from a grant of the EU Joint Programme - Neurodegenerative Disease

Research (project EPIC4ND, coordination: C.M.L.). This article uses data from the Berlin

Aging Study II (BASE-II) and the GendAge study, which were supported by the German

Federal Ministry of Education and Research under grant numbers #01UW0808; #16SV5536K,

#16SV5537, #16SV5538, #16SV5837, #01GL1716A and #01GL1716B. We thank all probands

of the BASE-II/GendAge study for their participation in this research. C. M. L. was supported

by the Heisenberg programme of the German Research Foundation (DFG; LI 2654/4-1).

Author contributions

Conceived and designed the study: HS, VMV and ID. Contributed study-specific data: VMV,

JH, VRZ, LB, and ID. Analysed the data: HS. Wrote the manuscript: HS, VMV and ID. All

authors revised and approved the manuscript.

Competing interests

The authors declare no competing interests.

Data availability statement

Due to concerns for participant privacy, data are available only upon reasonable request. Please

contact Ludmila Müller, scientific coordinator, at lmueller@mpib-berlin.mpg.de, for additional

16

information.

Ethics

All participants gave written informed consent. Medical assessments were conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Charité - Universitaetsmedizin Berlin (approval numbers EA2/029/09 and EA2/144/16) and were registered in the German Clinical Trials Registry as DRKS00009277 and DRKS00016157.

References

- 1. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. *Nat Rev Genet*. Jun 2018;19(6):371-384. doi:10.1038/s41576-018-0004-3
- 2. Jylhava J, Pedersen NL, Hagg S. Biological Age Predictors. *EBioMedicine*. Jul 2017;21:29-36. doi:10.1016/j.ebiom.2017.03.046
- 3. Horvath S. DNA methylation age of human tissues and cell types. Genome biology: Genome Biol; 2013. doi:10.1186/GB-2013-14-10-R115
- 4. Hannum G, Guinney J, Zhao L, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. *Mol Cell*. Jan 24 2013;49(2):359-367. doi:10.1016/j.molcel.2012.10.016
- 5. Vetter VM, Kalies CH, Sommerer Y, Bertram L, Demuth I. Seven-CpG DNA Methylation Age Determined by Single Nucleotide Primer Extension and Illumina's Infinium MethylationEPIC Array Provide Highly Comparable Results. *Front Genet*. 2021;12:759357. doi:10.3389/fgene.2021.759357
- 6. Levine ME, Lu AT, Quach A, et al. An epigenetic biomarker of aging for lifespan and healthspan. *Aging (Albany NY)*. Apr 18 2018;10(4):573-591. doi:10.18632/aging.101414
- 7. Lu AT, Quach A, Wilson JG, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. *Aging (Albany NY)*. Jan 21 2019;11(2):303-327. doi:10.18632/aging.101684
- 8. Belsky DW, Caspi A, Corcoran DL, et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. *Elife*. Jan 14 2022;11. doi:10.7554/eLife.73420
- 9. Chen BH, Marioni RE, Colicino E, et al. DNA methylation-based measures of biological age: meta-analysis predicting time to death. *Aging (Albany NY)*. Sep 28 2016;8(9):1844-1865. doi:10.18632/aging.101020
- 10. Oblak L, van der Zaag J, Higgins-Chen AT, Levine ME, Boks MP. A systematic review of biological, social and environmental factors associated with epigenetic clock acceleration. *Ageing Res Rev.* Aug 2021;69:101348. doi:10.1016/j.arr.2021.101348
- 11. Horstman AM, Dillon EL, Urban RJ, Sheffield-Moore M. The role of androgens and estrogens on healthy aging and longevity. *J Gerontol A Biol Sci Med Sci*. Nov 2012;67(11):1140-52. doi:10.1093/gerona/gls068

- 12. Lamberts SW, van den Beld AW, van der Lely AJ. The endocrinology of aging. *Science*. Oct 17 1997;278(5337):419-24. doi:10.1126/science.278.5337.419
- 13. Chakravarti S, Collins WP, Forecast JD, Newton JR, Oram DH, Studd JW. Hormonal profiles after the menopause. *Br Med J*. Oct 2 1976;2(6039):784-7. doi:10.1136/bmj.2.6039.784
- 14. Decaroli MC, Rochira V. Aging and sex hormones in males. *Virulence*. Jul 4 2017;8(5):545-570. doi:10.1080/21505594.2016.1259053
- 15. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. *J Clin Endocrinol Metab*. Sep 1984;59(3):551-5. doi:10.1210/jcem-59-3-551
- 16. Forti P, Maltoni B, Olivelli V, Pirazzoli GL, Ravaglia G, Zoli M. Serum dehydroepiandrosterone sulfate and adverse health outcomes in older men and women. *Rejuvenation Res.* Aug 2012;15(4):349-58. doi:10.1089/rej.2011.1248
- 17. Wang Y, Islam RM, Hussain SM, McNeil JJ, Davis SR. Associations Between Blood Concentrations of Sex Hormones and Physical Function in Community-Dwelling Older Women: A Prospective Cohort Study. *J Gerontol A Biol Sci Med Sci.* Apr 1 2024;79(4). doi:10.1093/gerona/glad287
- 18. Islam RM, Bell RJ, Handelsman DJ, et al. Associations between blood sex steroid concentrations and risk of major adverse cardiovascular events in healthy older women in Australia: a prospective cohort substudy of the ASPREE trial. *Lancet Healthy Longev*. Feb 2022;3(2):e109-e118. doi:10.1016/S2666-7568(22)00001-0
- 19. Berr C, Lafont S, Debuire B, Dartigues JF, Baulieu EE. Relationships of dehydroepiandrosterone sulfate in the elderly with functional, psychological, and mental status, and short-term mortality: a French community-based study. *Proc Natl Acad Sci U S A*. Nov 12 1996;93(23):13410-5. doi:10.1073/pnas.93.23.13410
- 20. Li R, E L, Zha N. Circulating dehydroepiandrosterone sulfate level and cardiovascular or all-cause mortality in the elderly population: a meta-analysis. *Ann Palliat Med.* Sep 2020;9(5):3537-3545. doi:10.21037/apm-20-441

- 21. Nawata H, Yanase T, Goto K, Okabe T, Ashida K. Mechanism of action of anti-aging DHEA-S and the replacement of DHEA-S. *Mech Ageing Dev*. Apr 30 2002;123(8):1101-6. doi:10.1016/s0047-6374(01)00393-1
- 22. Arlt W. Dehydroepiandrosterone and ageing. *Best Pract Res Clin Endocrinol Metab*. Sep 2004;18(3):363-80. doi:10.1016/j.beem.2004.02.006
- 23. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. *J Clin Endocrinol Metab*. Jan 2008;93(1):68-75. doi:10.1210/jc.2007-1792
- 24. Tivesten A, Vandenput L, Labrie F, et al. Low serum testosterone and estradiol predict mortality in elderly men. *J Clin Endocrinol Metab*. Jul 2009;94(7):2482-8. doi:10.1210/jc.2008-2650
- 25. Wang J, Fan X, Yang M, et al. Sex-specific associations of circulating testosterone levels with all-cause and cause-specific mortality. *Eur J Endocrinol*. May 2021;184(5):723-732. doi:10.1530/EJE-20-1253
- 26. Shadyab AH, Macera CA, Shaffer RA, et al. Ages at Menarche and Menopause and Reproductive Lifespan As Predictors of Exceptional Longevity in Women: The Women's Health Initiative HHS Public Access. Menopause 2017. p. 35-44. doi:10.1097/GME.0000000000000010
- 27. Ossewaarde ME, Bots ML, Verbeek ALM, et al. Age at menopause, cause-specific mortality and total life expectancy. Epidemiology2005. p. 556-562. doi:10.1097/01.EDE.0000165392.35273.D4
- 28. Jacobsen BK, Heuch I, Kvåle G. Age at Natural Menopause and All-Cause Mortality: A 37-Year Follow-up of 19,731 Norwegian Women. American Journal of Epidemiology: Oxford Academic; 2003. p. 923-929. doi:10.1093/AJE/KWG066
- 29. Rocca WA, Gazzuola-Rocca L, Smith CY, et al. Accelerated Accumulation of Multimorbidity After Bilateral Oophorectomy: A Population-Based Cohort Study. Mayo Clinic proceedings: NIH Public Access; 2016. p. 1577. doi:10.1016/J.MAYOCP.2016.08.002
- 30. Harbs J, Rinaldi S, Keski-Rahkonen P, et al. An epigenome-wide analysis of sex hormone levels and DNA methylation in male blood samples. *Epigenetics*. Dec 2023;18(1):2196759. doi:10.1080/15592294.2023.2196759

- 31. Hilser JR, Hartiala JA, Sriprasert I, et al. Effect of menopausal hormone therapy on methylation levels in early and late postmenopausal women. *Clin Epigenetics*. Jul 18 2022;14(1):90. doi:10.1186/s13148-022-01311-w
- 32. Stubbs TM, Bonder MJ, Stark AK, et al. Multi-tissue DNA methylation age predictor in mouse. *Genome Biol.* Apr 11 2017;18(1):68. doi:10.1186/s13059-017-1203-5
- 33. Levine ME, Lu AT, Chen BH, et al. Menopause accelerates biological aging. *Proc Natl Acad Sci U S A*. Aug 16 2016;113(33):9327-32. doi:10.1073/pnas.1604558113
- 34. Kusters CDJ, Paul KC, Lu AT, et al. Higher testosterone and testosterone/estradiol ratio in men are associated with decreased Pheno-/GrimAge and DNA-methylation based PAI1. *Geroscience*. Jun 27 2023. doi:10.1007/s11357-023-00832-3
- 35. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. *J Clin Endocrinol Metab*. Oct 1999;84(10):3666-72. doi:10.1210/jcem.84.10.6079
- 36. Bertram L, Böckenhoff A, Demuth I, et al. Cohort profile: The Berlin aging study II (BASE-II). International Journal of Epidemiology2014. p. 703-712. doi:10.1093/ije/dyt018
- 37. Demuth I, Banszerus V, Drewelies J, et al. Cohort profile: Follow-up of a Berlin Aging Study II (BASE-II) subsample as part of the GendAge study. BMJ Open2021. p. 6-8. doi:10.1136/bmjopen-2020-045576
- 38. Martin KA, Manson JE. Approach to the patient with menopausal symptoms. *J Clin Endocrinol Metab*. Dec 2008;93(12):4567-75. doi:10.1210/jc.2008-1272
- 39. Vetter VM, Kalies CH, Sommerer Y, et al. Relationship Between 5 Epigenetic Clocks, Telomere Length, and Functional Capacity Assessed in Older Adults: Cross-Sectional and Longitudinal Analyses. *The Journals of Gerontology: Series A.* 2022;77(9):1724-1733. doi:10.1093/gerona/glab381
- 40. Vetter VM, Meyer A, Karbasiyan M, Steinhagen-Thiessen E, Hopfenmuller W, Demuth I. Epigenetic Clock and Relative Telomere Length Represent Largely Different Aspects of Aging in the Berlin Aging Study II (BASE-II). *J Gerontol A Biol Sci Med Sci.* Jan 1 2019;74(1):27-32. doi:10.1093/gerona/gly184

- 41. Nothlings U, Hoffmann K, Bergmann MM, Boeing H. Fitting portion sizes in a self-administered food frequency questionnaire. *J Nutr.* Dec 2007;137(12):2781-6. doi:10.1093/jn/137.12.2781
- 42. Vikan T, Schirmer H, Njolstad I, Svartberg J. Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromso Study. *Eur J Endocrinol*. Sep 2009;161(3):435-42. doi:10.1530/EJE-09-0284
- 43. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. *J Clin Endocrinol Metab*. Jun 2012;97(6):2050-8. doi:10.1210/jc.2011-2591
- 44. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. *Eur J Endocrinol*. Dec 2013;169(6):725-33. doi:10.1530/EJE-13-0321
- 45. La Vecchia C, Brinton LA, McTiernan A. Menopause, hormone replacement therapy and cancer. *Maturitas*. Aug 25 2001;39(2):97-115. doi:10.1016/s0378-5122(01)00213-4
- 46. Boardman HM, Hartley L, Eisinga A, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. *Cochrane Database Syst Rev.* Mar 10 2015;2015(3):CD002229. doi:10.1002/14651858.CD002229.pub4
- 47. Maggio M, Ceda GP, Lauretani F, et al. Relationship between higher estradiol levels and 9-year mortality in older women: the Invecchiare in Chianti study. *J Am Geriatr Soc.* Oct 2009;57(10):1810-5. doi:10.1111/j.1532-5415.2009.02464.x
- 48. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. *N Engl J Med.* Jun 19 1997;336(25):1769-75. doi:10.1056/NEJM199706193362501
- 49. Ohlsson C, Labrie F, Barrett-Connor E, et al. Low serum levels of dehydroepiandrosterone sulfate predict all-cause and cardiovascular mortality in elderly Swedish men. *J Clin Endocrinol Metab*. Sep 2010;95(9):4406-14. doi:10.1210/jc.2010-0760
- 50. Trivedi DP, Khaw KT. Dehydroepiandrosterone sulfate and mortality in elderly men and women. *J Clin Endocrinol Metab*. Sep 2001;86(9):4171-7. doi:10.1210/jcem.86.9.7838

- 51. Voznesensky M, Walsh S, Dauser D, Brindisi J, Kenny AM. The association between dehydroepiandosterone and frailty in older men and women. *Age Ageing*. Jul 2009;38(4):401-6. doi:10.1093/ageing/afp015
- 52. Fahy GM, Brooke RT, Watson JP, et al. Reversal of epigenetic aging and immunosenescent trends in humans. *Aging Cell*. Dec 2019;18(6):e13028. doi:10.1111/acel.13028

Table 1: Characteristics of the 1,404 BASE-II participants at baseline (T0) of which 1,015 were reassessed on average 7.3 years later (T1) as included in the current analyses

	Men			Women		
W:-1-1	Mean	SD		Mean	SD	
Variables	Mdn	IQR	n	Mdn	IQR	n
Age T0 (years)	69.02	3.78	731	68.41	3.58	673
Age T1 (years)	75.50	4.01	514	75.66	3.55	501
Interval T0-T1 (years)	7.02	1.37	514	7.63	1.46	501
Pack years T0 ^a	5.00	21.25	702	0.00	6.69	652
Alcohol T0 (g/d) ^a	12.73	21.30	717	5.32	10.65	656
BMI T0 (kg/m2)	27.25	3.61	727	26.54	4.69	668
Sex hormone level T0 ^a						
Estradiol (pmol/l)	84.45	53.49	725	9.20	33.89	667
DHEAS (ng/ml)	1055.50	819.60	728	736.25	739.84	667
FAI	36.69	13.38	718	0.90	1.25	641
DNAmA T0 (years)						
Horvath	65.17	4.97	488	62.81	4.64	468
Hannum	56.54	4.36	488	53.89	4.28	468
7-CpG clock	67.64	7.68	714	65.02	7.39	635
PhenoAge	54.92	5.43	488	52.53	5.48	468
GrimAge	72.17	3.92	488	68.55	3.84	468

Note. ^a=Median + Inter Quartile Range, SD=Standard Deviation, Mdn=Median, IQR= Inter Quartile Range, FAI=Free Androgen Index, DNAmA=DNA methylation age (years).

Table 2: Sex hormone level and DNAmAA estimators of participants who attended both baseline and follow-up assessments

	Men				Women						
	T0 (2009-2014) T1 (2018-2020)				T0 (2009-2014)	T1 (2018-2020)					
X7 ' 11	Mean (SD)	Mean (SD)		p-value	Mean (SD)	Mean (SD)		p-value			
Variables	Mdn (IQR)	Mdn (IQR)			Mdn (IQR)	Mdn (IQR)					
DNAmAA (years)											
Horvath	0.62 (4.21)	0.46 (3.98)	443	0.258	-0.61 (4.07)	-0.54 (3.69)	400	0.651^{b}			
Hannum	0.71 (3.46)	0.81 (4.00)	443	0.414	-0.77 (3.31)	-0.74 (3.53)	400	0.794^{b}			
7-CpG clock	1.05 (6.86)	0.97 (5.49)	449	0.735	-1.22 (6.66)	-0.96 (5.30)	402	0.275^{b}			
PhenoAge	0.31 (4.48)	0.67 (5.42)	443	0.065	-0.29 (4.54)	-0.61 (5.04)	400	0.104^{b}			
GrimAge	1.11 (3.00)	1.50 (3.23)	443	< 0.001	-1.02 (2.73)	-1.34 (2.86)	400	0.004^{b}			
DunedinPACE (biol./chron.)	1.03 (0.11)	1.10 (0.12)	490	< 0.001	0.98 (0.10)	1.05 (0.11)	468	<0.001 ^b			
Sex hormone level ^a											
Estradiol (pmol/l)	84.00 (53.78)	97.40 (48.30)	495	< 0.001	9.20 (29.77)	9.20 (25.10)	487	0.786^{c}			
DHEAS (ng/ml)	1074.28 (847.38)	889.00 (699.0)	499	< 0.001	743.20 (682.27)	643.00 (604.80)	486	<0.001°			
FAI	37.08 (13.99)	26.32 (9.91)	491	< 0.001	0.89 (1.19)	0.50 (0.82)	466	<0.001°			

Note. ^a=Median (Inter Quartile Range), ^b=paired t-test, ^c=Wilcoxon signed-rank test, Mdn=Median, IQR=Inter Quartile Range, SD=Standard Deviation, DNAmAA=DNA methylation age acceleration (years), FAI=Free Androgen Index, T0=Baseline assessment, T1=Follow-up assessment. A Wilcoxon signed-rank test was used to test for differences in median sex hormone concentration between baseline and follow-up assessment. To test for differences in mean DNAmAA a paired t-test was calculated. Only participants with available data at both time points are included in this table.

Table 3: Multiple linear regression analyses of DNAmAA on estradiol, DHEAS and FAI for older participants of the BASE-II at baseline

		Men								Women							
Hormone	DNAmAA	N/ - 1 - 1	Estimate	ar.	CI	CI	1	n	Estimate	ar.	CI	CI	1				
		Model	Estimate	SE	LL	UL	p-value			SE	LL	UL	p-value	n			
Estradiol	Horvath	1	0.007	0.005	-0.002	0.015	0.141	446	0.008	0.007	-0.006	0.022	0.288	406			
		2	0.004	0.005	-0.005	0.013	0.390	420	0.004	0.007	-0.010	0.019	0.571	384			
	GrimAge	1	0.001	0.003	-0.005	0.007	0.741	446	0.002	0.005	-0.008	0.011	0.740	406			
		2	0.002	0.003	-0.003	0.008	0.400	420	-0.004	0.005	-0.013	0.005	0.414	384			
	DunedinPACE	1	2.7E-5	1.1E-4	-1.9E-4	2.4E-4	0.802	483	-1.6E-4	1.7E-4	-4.9E-4	1.7E-4	0.346	464			
		2	6.6E-6	1.1E-4	-2.1E-4	2.2E-4	0.952	455	-3.6E-4	1.7E-4	-0.001	-3.0E-5	0.032	433			
DHEAS	Horvath	1	-4.8E-4	3.3E-4	-0.001	1.6E-4	0.144	449	-3.1E-4	4.0E-4	-0.001	5.E-4	0.441	405			
		2	-0.001	3.4E-4	-0.001	-6.2E-5	0.032	424	-4.3E-4	4.2E-4	-0.001	4.E-4	0.300	383			
	GrimAge	1	1.2E-4	2.3E-4	-3.3E-4	0.001	0.603	449	3.2E-4	2.6E-4	-2.E-4	0.001	0.219	405			
		2	-9.0E-5	2.1E-4	-0.001	3.3E-4	0.677	424	2.9E-4	2.5E-4	-2.1E-4	0.001	0.260	383			
	DunedinPACE	1	-1.8E-6	7.8E-6	-1.7E-5	1.3E-5	0.817	486	4.5E-6	9.5E-6	-1.E-5	2.E-5	0.637	464			
		2	-8.6E-7	7.8E-6	-1.6E-5	1.4E-5	0.912	459	1.2E-5	9.3E-6	-6.E-6	3.E-5	0.185	433			
FAI	Horvath	1	0.011	0.016	-0.021	0.043	0.503	444	-0.020	0.141	-0.297	2.6E-1	0.888	387			
		2	0.004	0.017	-0.029	0.038	0.799	418	-0.046	0.144	-0.328	0.237	0.751	367			
	GrimAge	1	-0.026	0.011	-0.049	-0.004	0.021	444	0.019	0.094	-0.166	0.203	0.842	387			
		2	-0.019	0.011	-0.041	0.002	0.072	418	0.028	0.088	-0.145	0.202	0.748	367			
	DunedinPACE	1	-0.001	4.E-4	-0.001	2.E-4	0.123	480	0.003	0.003	-0.004	0.009	0.382	443			
		2	-2.E-4	4.E-4	-0.001	0.001	0.613	452	0.001	0.003	-0.005	0.007	0.737	415			

Model 1: unadjusted; Model 2: adjusted for chronological age, smoking (pack years), alcohol (g/d), BMI. Note: DNAmAA=DNA methylation age acceleration, SE=Standard Error, CI=Confidence Interval, LL=Lower Limit, UL=Upper Limit.

Table 4: Longitudinal multiple linear regression analyses of ΔDNAmAA on Δestradiol, ΔDHEAS and ΔFAI for older participants of the BASE-II

					Mer	ı			Women						
ΔHormone	ΔDNAmAA	N/L- 1-1	Estimate	CE.	CI	CI	1	n	Estimate	SE	CI	CI	1	n	
		Model	Estimate	SE	LL	UL	p-value				LL	UL	p-value		
Estradiol	Horvath	1	-3.8E-4	0.004	-0.007	0.007	0.916	433	-0.001	0.004	-0.009	0.008	0.903	395	
		2	-0.001	0.004	-0.009	0.007	0.836	408	-0.002	0.004	-0.011	0.007	0.686	375	
	GrimAge	1	-0.004	0.003	-0.009	0.001	0.110	433	-0.001	0.003	-0.007	0.005	0.741	395	
		2	-0.002	0.003	-0.009	0.004	0.522	408	4.9E-4	0.004	-0.006	0.007	0.890	375	
	DunedinPACE	1	1.7E-5	8.2E-5	-1.4E-4	1.8E-4	0.832	472	-8.3E-5	9.2E-5	-2.6E-4	9.9E-5	0.371	455	
		2	9.5E-5	1.0E-4	-1.1E-4	3.0E-4	0.357	445	5.3E-5	1.1E-4	-1.6E-4	2.6E-4	0.620	424	
DHEAS	Horvath	1	9.1E-5	3.9E-4	-0.001	0.001	0.818	436	-8.5E-5	0.001	-0.001	0.001	0.874	394	
		2	2.6E-5	4.1E-4	-0.001	0.001	0.950	412	-1.6E-4	0.001	-0.001	0.001	0.757	374	
	GrimAge	1	-6.6E-5	2.9E-4	-0.001	0.001	0.822	436	-2.4E-4	3.9E-4	-0.001	0.001	0.542	394	
		2	-1.7E-4	3.2E-4	-0.001	4.6E-4	0.604	412	-3.8E-4	4.2E-4	-0.001	4.4E-4	0.361	374	
	DunedinPACE	1	-3.4E-5	8.7E-6	-5.1E-5	-1.7E-5	< 0.001	475	-2.7E-5	1.1E-5	-5.0E-5	-4.6E-6	0.018	455	
		2	-2.2E-5	9.6E-6	-4.1E-5	-3.2E-6	0.022	449	-3.4E-5	1.2E-5	-5.8E-5	-1.0E-5	0.005	424	
FAI	Horvath	1	-0.003	0.012	-0.027	0.021	0.794	430	-0.134	0.120	-0.370	0.101	0.263	377	
		2	-0.009	0.017	-0.042	0.024	0.605	405	-0.069	0.219	-0.499	0.361	0.752	359	
	GrimAge	1	-0.008	0.009	-0.026	0.010	0.374	430	-0.007	0.087	-0.179	0.164	0.932	377	
		2	-0.012	0.013	-0.038	0.014	0.359	405	0.109	0.171	-0.227	0.445	0.522	359	
	DunedinPACE	1	-3.6E-4	2.8E-4	-0.001	1.8E-4	0.189	468	0.003	0.003	-0.002	0.008	0.243	435	
		2	-2.6E-4	4.0E-4	-0.001	0.001	0.523	441	0.009	0.005	-0.001	0.019	0.071	407	

Model 1: unadjusted; Model 2: adjusted for chronological age at baseline, years since baseline assessment, baseline hormone concentration, baseline DNAmAA, baseline smoking (pack years), alcohol (g/d), BMI. Note: DNAmAA=DNA methylation age acceleration, SE=Standard Error, CI=Confidence Interval, LL=Lower Limit, UL=Upper Limit.

Figure 1: Case selection and final analytic datasets. Selected participants of the Berlin Aging Study II (BASE-II) were reassessed on average after 7.3 years. If the number of participants varied due to differences in the availability of hormone or epigenetic clock data, the maximum number of observations was reported in this flow chart. Individual sample sizes are indicated with each statistical analysis.

